PCPaul Cummins

Paul Cummins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul Cummins has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Primary Percutaneous Coronary Intervention Guided by High‐Definition Intravascular Ultrasound (The SPECTRUM Study)

    by Frederik T. W. Groenland, Annemieke C. Ziedses Des Plantes, Tara Neleman, Jurgen M. R. Ligthart, Karen T. Witberg, Rutger‐Jan Nuis, Jeroen M. Wilschut, Roberto Diletti, Wijnand K. Den Dekker, Isabella Kardys, et al.

    Background: Limited data are available on the use of intravascular ultrasound (IVUS) in patients presenting with ST‐segment elevation myocardial infarction (STEMI). Aims: This study aimed to assess the impact of IVUS‐guided primary percutaneous coronary intervention (PCI). Methods: SPECTRUM (NCT05007535) was a prospective, single‐center, observational cohort study. STEMI patients presenting within 12 h after symptom onset with stable hemodynamics and undergoing primary PCI of a native culprit lesion (angiographic reference diameter ≥ 2.25 mm) were eligible. Pre‐intervention, post‐intervention and post‐optimization (if applicable) HD‐IVUS pullbacks were obtained per protocol. The primary endpoint was target vessel failure (TVF) at 12 months, a composite of cardiovascular death, target vessel myocardial infarction, and target vessel revascularization. The secondary endpoint was presence of IVUS‐guided optimization. Results: A total of 200 STEMI patients were included. Mean age was 62.1 (±12.5) years, 69% were male, 11.0% had diabetes and the left anterior descending was the culprit vessel in 44.0%. IVUS‐guided optimization was performed in 41.1%. Optimal PCI, based on predefined IVUS criteria, increased from 52.1% post intervention to 65.5% post optimization ( p < 0.001). A stent‐edge plaque burden > 50% was the main reason for not achieving optimal PCI results after IVUS‐guided optimization (94.4%). TVF at 12 months occurred in 3.0% (95% CI 1.1%−6.4%). Conclusions: SPECTRUM is the first dedicated prospective study demonstrating the potential of IVUS to optimize outcomes in a primary PCI setting. IVUS guidance in primary PCI was safe, significantly increased the number of STEMI patients with an optimal PCI result and resulted in low rates of TVF at 12 months.

  • Open Access

    Reviewers and Awards 2025-2026

    by Nico Bruining, Robert van der Boon, Isabella Kardys, Paul Cummins, Roderick Scherptong, David Duncker, Rafael Vidal-Perez, Joost Lumens

  • Open Access

    Reviewers and awards

    by Nico Bruining, Robert van der Boon, Isabella Kardys, Paul Cummins, Joost Lumens

  • Open Access

    Timing of Complete Multivessel Revascularization in Patients Presenting with Non-ST-Elevation Acute Coronary Syndrome

    by Jacob J. Elscot, Hala Kakar, Paola Scarparo, Wijnand K. Den Dekker, Johan Bennett, Carl E. Schotborgh, Rene van der Schaaf, Manel Sabaté, Raúl Moreno, Koen Ameloot, et al.

    Background: Multivessel coronary artery disease (MVD) is highly prevalent in patients presenting with non-ST-segment elevation myocardial infarction (NSTE-ACS) and is associated with worse clinical outcomes compared with single vessel disease patients. Complete revascularization of the culprit and all significant non-culprit lesions reduces the incidence of major adverse cardiac events, but the optimal timing of non-culprit artery revascularization remains unclear. Methods: This prespecified substudy of the randomized BIOVASC trial included patients who presented with NSTE-ACS and MVD, defined as ≥ 1 non-culprit related coronary artery with a diameter of ≥ 2.5 mm and ≥ 70% stenosis as per visual estimation or positive coronary physiology testing. Risk differences of the composite of all-cause mortality, myocardial infarction, unplanned ischemia driven revascularization or cerebrovascular events and its individual components were compared between the patients who were randomized to immediate and staged complete revascularization at 30 days and 1 year. Results: The BIOVASC trial enrolled 1525 patients, 917 patients presented with NSTE-ACS, of whom 459 were allocated to the immediate complete and 458 to the staged complete revascularization group. The incidences of the primary composite outcome were similar in the two groups (7.9% vs. 10.1%, risk difference 2.2%, 95%CI −1.5 to 6.0, p = 0.24). Immediate complete revascularization was associated with a significant reduction in the incidence of myocardial infarction (2.0% vs. 5.3%, risk difference 3.3%, 95% confidence interval [CI] 0.9 to 5.7, p = 0.008), which was maintained after exclusion of procedure related myocardial infarctions occurring at the index or staged procedure (2.0% vs. 4.4%, risk difference 2.4%, 95%CI 0.1 to 4.7, p = 0.039). Unplanned ischemia driven revascularizations were also reduced in the immediate complete revascularization group (4.2% vs. 7.8%, risk difference 3.5%, 95%CI 0.4 to 6.6, p = 0.025). Conclusions: Immediate complete revascularization is safe in patients with NSTE-ACS and MVD and was associated with a reduction in myocardial infarctions and unplanned ischemia driven revascularizations at 1 year. Clinical Perspective: What Is New? - This prespecified subanalysis of the BIOVASC trial shows that all spontaneous myocardial infarctions between the index and staged procedure occurred in the population of patients that initially presented with NSTE-ACS. At 30 days and 1 year patients randomized to immediate complete revascularization have fewer myocardial infarctions and unplanned ischemia driven revascularizations. What Are the Clinical Implications? - Immediate complete revascularization appears to be a safe strategy and can be a reasonable option for complete revascularization in patients presenting with NSTE-ACS and multivessel disease - In patients presenting with NSTE-ACS and multivessel disease, misjudgment of the culprit lesion or presence of multiple vulnerable plaques could have a role in the reduction of early occurring myocardial infarctions when performing an immediate complete strategy.

  • Open Access

    Artificial Intelligence and Transcatheter Interventions for Structural Heart Disease: A glance at the (near) future

    by Joana Maria Ribeiro, Patricio Astudillo, Ole de Backer, Ricardo Budde, Rutger Jan Nuis, Jeanette Goudzwaard, Nicolas M Van Mieghem, Joost Lumens, Peter Mortier, Francesco Mattace-Raso, et al.


  • Open Access

    Impact of Poststenting Fractional Flow Reserve on Long-Term Clinical Outcomes

    by Roberto Diletti, Kaneshka Masdjedi, Joost Daemen, Laurens J.C. van Zandvoort, Tara Neleman, Jeroen Wilschut, Wijnand K. Den Dekker, Rutger J. van Bommel, Miguel Lemmert, Isabella Kardys, et al.

    Background: Fractional flow reserve (FFR)-guided treatment has been demonstrated to improve percutaneous coronary intervention (PCI) results. However, little is known on the long-term impact of low post-PCI FFR. Methods: This is a large prospective all comers study evaluating the impact of post-PCI FFR on clinical outcomes. All patients undergoing successful PCI were eligible for enrollment. FFR measurements were performed immediately after PCI when the operator considered the angiographic result acceptable and final. No further action was undertaken based on the post-PCI result. Suboptimal post-PCI FFR was defined as FFRP =0.707), cardiac death (HR, 1.55 [95% CI, 0.72–3.36], P =0.261), any myocardial infarction (HR, 1.53 [95% CI, 0.78–3.02], P =0.217). A vessel level analysis showed a higher rate of target vessel revascularization (HR, 1.91 [95% CI, 1.06–3.44], P =0.030) and a tendency toward higher rate of stent thrombosis (HR, 2.89 [95% CI, 0.88–9.48], P =0.081) with final post-PCI FFR<0.90. Conclusions: Suboptimal post-PCI FFR has only a moderate impact on major adverse cardiac event but coronary arteries with a post-PCI FFR<0.90 have a higher rate of target vessel revascularization.


  • Open Access

    International feasibility trial on the use of an interactive mobile health platform for cardiac rehabilitation: protocol of the Diversity 1 study

    by Manuel Cruz Gonzalez-Garcia, Farhad Fatehi, Martijn Scherrenberg, Robin Henriksson, Adrian Maciejewski, Jorge Salamanca Viloria, Paul Cummins, Ines Frederix, Antonio Manuel Rojas Gonzalez, Lukasz Koltowski, et al.

    Introduction The implementation of home-based cardiac rehabilitation has demonstrated potential to increase patient participation, but the content and the delivering of the programmes varies across countries. The objective of this study is to investigate whether an Australian-validated mobile health (mHealth) platform for cardiac rehabilitation will be accepted and adopted irrespectively from the existing organisational and contextual factors in five different European countries. Methods and analysis This international multicentre feasibility study will use surveys, preliminary observations and analysis to evaluate the use and the user’s perceptions (satisfaction) of a validated mHealth platform in different contextual settings. Ethics and dissemination This study protocol has been approved by the Australian research organisation CSIRO and the respective ethical committees of the European sites. The dissemination of this trial will serve as a ground for the further implementation of an international large randomised controlled trial which will contribute to an effective global introduction of mHealth into daily clinical practice.


  • Open Access

    Organization of outcome-based quality improvement in Dutch heart centres

    by Dennis van Veghel, Edgar J Daeter, Matthijs Bax, Giovanni Amoroso, Yuri Blaauw, Cyril Camaro, Paul Cummins, Frank R Halfwerk, Inez J Wijdh-Den Hamer, Jonas S S G de Jong, et al.

    Fourteen Dutch heart centres collected patient-relevant outcomes to support quality improvements in a value-based healthcare initiative that began in 2012. This study aimed to evaluate the current state of outcome-based quality improvement within six of these Dutch heart centres. Interviews and questionnaires among physicians and healthcare professionals in the heart centres were combined in a mixed-methods approach. The analysis indicates that the predominant focus of the heart centres is on the actual monitoring of outcomes. A systematic approach for the identification of improvement potential and the selection and implementation of improvement initiatives is lacking. The organizational context for outcome-based quality improvement is similar in the six heart centres. Although these heart centres in the Netherlands measure health outcomes for the majority of cardiac diseases, the actual use of these outcomes to improve quality of care remains limited. The main barriers are limitations regarding (i) data infrastructure, (ii) a systematic approach for the identification of improvement potential and the selection and implementation of improvement initiatives, (iii) governance in which roles and responsibilities of physicians regarding outcome improvement are formalized, and (iv) implementation of outcomes within hospital strategy, policy documents, and the planning and control cycle.


  • Open Access

    Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials

    by Jin-Zan Cai, Yong-Xiang Zhu, Xin-Yu Wang, Christos V Bourantas, Javaid Iqbal, Hao Zhu, Paul Cummins, Sheng-Jie Dong, Anthony Mathur, Yao-Jun Zhang

    Objective The study sought to compare angiographic and clinical outcomes of new-generation drug-eluting stents (DES) versus drug-coated balloon (DCB) in patients with coronary in-stent restenosis (ISR). Design Meta-analysis using data from randomised trial found by searches on PubMed, the Cochrane Library, ClinicalTrials.gov and websites of major cardiovascular congresses. Setting Only randomised trials comparing DES with DCB were included. Participants Patients with ISR in the included trials. Interventions New-generation DES versus DCB. Outcomes The angiographic and clinical outcomes including cardiac death, all-cause death, myocardial infarction, target lesion revascularisation (TLR), target vessel revascularisation (TVR), major adverse cardiac events (MACE) and stent thrombosis were investigated. Results Five trials including 913 patients were eligible and included. Pooled analysis in angiographic results identified that new-generation DES were associated with higher acute luminal gain (−0.31 mm, 95% CI −0.42 to −0.20, PConclusions Interventions with new-generation DES appear to be associated with significant reduction in per cent diameter stenosis and TLR at short-term follow-up, but had similar MACE, myocardial infarction and cardiac death for patients with coronary ISR compared with DCB. Appropriately powered studies with longer term follow-up are warranted to confirm these findings.